Is there a role for neoadjuvant chemotherapy or abiraterone for a young man with very high risk prostate cancer without imaging evidence of metastasis?

Topics: Genitourinary Cancers • Medical Oncology

For example in a <50 years old man with Gleason 9, PSA > 50 disease?

Answer from: Medical Oncologist at Academic Institution

At present, there is no data to support the use of androgen deprivation therapy, abiraterone, or docetaxel prior to radical prostatectomy in men with high risk localized non-metastatic prostate cancer. However, in STAMPEDE, over 500 men with such high risk non-metastatic features were enrolled, and...

Related Questions